Merck — The company is in final-stage testing for an intravenous treatment that would protect against C. diff bacteria for three months.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Sanofi — Sanofi is in mid-stage trials for a C. diff vaccine, which would be the only one on the market, if approved. The trials will conclude in 2018.
Actelion — The company is in late-stage testing of a new antibiotic to combat C. diff, cadazolid. It expects results in 2016.
Shire — As of March 2014, the company completed mid-stage safety and efficacy trials for its VP20621, acquired from ViroPharma in a takeover last year.
Cubist Pharmaceuticals — The company is in final-stage testing for the antibiotic surotomycin. It expects final data by 2015.
Synthetic Biologics — The company is entering mid-stage testing for its C. diff-preventing pill.
More Articles on Infection Control & Clinical Quality:
FDA Recommends 2 New Anti-MRSA Agents
Lucrative Treatments Overlooked For Lists of Unecessary Procedures
Direct Patient Education Improves Adherence to Drug-Use Guidelines
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
